The Biochemical Selectivity of Novel COX-2 Inhibitors in Whole Blood Assays of COX-isozyme Activity

References

• Dennis EA. Phospholipase A2 in eicosanoid generation. Am J Respir Crit Care Med 2000;161:S32–5
   PubMed Web of Science ®Google Scholar
• Marnett LJ, Rowlinson SW, Goodwin DC, Kalgutkar AS, Lanzo CA. Arachidonic acid oxygenation by COX-1 and COX-2. Mechanisms of catalysis and inhibition. J Biol Chem 1999;13: 22903–6
   Web of Science ®Google Scholar
• Smith WL, Langenbach R. Why there are two cyclooxygenase isozymes. J Clin Invest 2001;12:1491–5
   Web of Science ®Google Scholar
• Jakobsson PJ, Thoren S, Morgenstern R, Samuelsson B. Identification of the human prostaglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target. Proc Natl Acad Sci USA 1999;96:7220–5
   PubMed Web of Science ®Google Scholar
• Tanioka T, Nakatani Y, Semmyo N, Murakami M, Kudo I. Molecular identification of cytosolic prostaglandin E2 synthase that is functionally coupled with cyclooxygenase-1 in immediate prostaglandin E2 biosynthesis. J Biol Chem 2000;275: 32775–82
   PubMed Web of Science ®Google Scholar
• Xie W, Chipman JG, Robertson DL, Erikson RL, Simmons DL. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci USA 1991;88:2692–6
   PubMed Web of Science ®Google Scholar
• Kujubu DA, Fletcher BS, Varnum BC, Lim RW, Herscham HR. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem 1991;266: 12866–72
   PubMed Web of Science ®Google Scholar
• Fitzgerald GA, Patrono C. The antiinflammatory properties and safety of coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001;345:433–42
   PubMed Web of Science ®Google Scholar
• Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Bosi Ferraz M, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ. A double-blind comparison of rofecoxib and naproxen on the incidence of clinically important upper gastrointestinal events: the VIGOR Trial. N Engl J Med 2000;343:1520–8
   PubMed Web of Science ®Google Scholar
• Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, Burr AM, Zhao WW, Kent JD, Leffkowith JB, Verburg K, Geis GS. Gastrointestinal toxicity with celecoxib vs non steroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS Study: a randomized controlled trial. JAMA 2000;284:1247–55
   PubMed Web of Science ®Google Scholar
• Ehrich EW, Dallob A, De Lepeleire I, Van Hecken A, Riendeau D, Yuan W, Porras A, Wittreich J, Seibold JR, De Schepper P, Mehlisch DR, Gertz BJ. Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model. Clin Pharmacol Ther 1999;65:336–47
   PubMed Web of Science ®Google Scholar
• McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, Fitzgerald GA. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA 1999;96:272–7
   PubMed Web of Science ®Google Scholar
• Talley JJ, Brown DL, Carter JS, Graneto MJ, Koboldt CM, Masferrer JL, Perkins WE, Rogers RS, Shapper AF, Zhang YY, Zweifel BS, Seibert K. 4-[5-Methyl-3-phenylisoxazol-4-yl]-benzenesulfonamide, valdecoxib: a potent and selective inhibitor of COX-2. J Med Chem 2000;43:775–7
   PubMed Web of Science ®Google Scholar
• Riendeau D, Percival MD, Brideau C, Charleson S, Dube D, Ethier D, Falgueyret JP, Friesen RW, Gordon R, Greig G, Guay J, Mancini J, Ouellet M, Wong E, Xu L, Boyce S, Visco D, Girard Y, Prasit P, Zamboni R, Rodger IW, Gresser M, Ford-Hutchinson AW, Young RN, Chan CC. Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J Pharmacol Exp Ther 2001;296: 558–66
   PubMed Web of Science ®Google Scholar
• Riendeau D, Percival MD, Boyce S, Brideau C, Charleson S, Cromlish W, Ethier D, Evans J, Falgueyret JP, Ford-Hutchinson AW, Gordon R, Greig G, Gresser M, Guay J, Kargman S, Léger S, Mancini JA, O’Neill G, Ouellet M, Rodger IW, Therien M, Wang Z, Webb JK, Wong E, Chan CC. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor. Br J Pharmacol 1997;121: 105–17
   PubMed Web of Science ®Google Scholar
• Leblanc Y, Roy P, Boyce S, Brideau C, Chan CC, Charleson S, Gordon R, Grimm J, Guay S, Léger C, Li CS, Riendeau D, Visco D, Wang Z, Xu LJ, Prasit P. SAR in the alkoxy lactone series: the discovery of DFP, a potent and orally active COX-2 inhibitor. Bioorg Med Chem Lett 1999;9: 2207–12
   PubMed Web of Science ®Google Scholar
• Patrignani P, Panara MR, Greco A, Fusco O, Natoli C, Iacobelli S, Cipollone F, Ganci A, Crèminon C, Maclouf J, Patrono C. Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. J Pharmacol Exp Ther 1994;271:1705–12
   PubMed Web of Science ®Google Scholar
• Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 1982;69:1366–72
   PubMed Web of Science ®Google Scholar
• Patrono C, Ciabattoni G, Pinca E, Pugliese F, Castrucci G, De Salvo A, Satta M.A, Peskar BA. Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. Thromb Res 1980;17: 317–27
   PubMed Web of Science ®Google Scholar
• Ciabattoni G, Pugliese F, Spaldi M, Cinotti GA, Patrono C. Radioimmunoassay measurement of prostaglandin E2 and F2α in human urine. J Endocrinol Invest 1979;2: 173–82
   PubMed Web of Science ®Google Scholar
• De Lean A, Munson PJ, Rodbard D. Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay, and physiological dose-response curves. Am J Physiol 1978;235:E97–102
   PubMed Web of Science ®Google Scholar
• Brooks P, Emery P, Evans JF, Fenner H, Hawkey CJ, Patrono C, Smolen J, Breedveld F, Day D, Dougados M, Ehrich EW, Gijon-Banos J, Kvien TK, Van Rijswijk MH, Warner T, Zeidler H. Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2. Rheumatology 1999;38: 779–88
   PubMed Web of Science ®Google Scholar
• Patrono C, Patrignani P, Garcìa Rodriguez LA. Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs. J Clin Invest 2001;108:7–13
   PubMed Web of Science ®Google Scholar
• Knott L. Treating osteoarthritis in practice-The TOP study. Curr Med Res Opin 2000;16:147–52
   PubMed Web of Science ®Google Scholar
• Van Hecken A, Schwartz JI, Depré M, De Lepeleire I, Dallob A, Tanaka W, Wynants K, Buntinx A, Arnout J, Wong PH, Ebel DL, Gertz BJ, De Schepper PJ. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol 2000;40: 1109–20
   PubMed Web of Science ®Google Scholar
• Patrignani P, Panara MR, Santini G, Dallob A, Moreland W, Chatham W, Punzi L, Todesco S, Riente L, Bombardieri S, Amin A, Abramson S, Ehrich E, Patrono C. Biochemical selectivity of rofecoxib in rheumatoid arthritis. 11th International Conference on Advances in Prostaglandin and Leukotriene Research: Basic Science and New Clinical Applications. Florence (Italy), 2000 June 4–8;19 (Abstr)
   Google Scholar
• Wight NJ, Gottesdiener K, Garlick NM, Atherton CT, Novak S, Gertz BJ, Calder NA, Co J, Wong P, Dallob A, Hawkey CJ Rofecoxib, a COX-2 inhibitor, does not inhibit human gastric mucosal prostaglandin production. Gastroenterology 2001;120:867–73
   PubMed Web of Science ®Google Scholar
• Panara MR, Renda G, Sciulli MG, Santini G, Di Giamberardino M, Rotondo MT, Tacconelli S, Seta F, Patrono C, Patrignani P. Dose-dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects. J Pharmacol Exp Ther 1999;290:276–80
   PubMed Web of Science ®Google Scholar
• Brater DC, Harris C, Redfern JS, Gertz BJ. Renal effects of COX-2-selective inhibitors. Am J Nephrol 2001;21:1–15
   PubMed Web of Science ®Google Scholar
• Catella-Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ, Demarco S, Tournier RN, Sachin NV, Fitzgerald GA. Cyclooxygenase inhibitors and platelet effects of aspirin. N Engl J Med 2001;345:1809–17
   PubMed Web of Science ®Google Scholar
• Ouellett M, Riendeau D, Percival MD. A high level of cyclooxygenase-2 inhibitor selectivity is associated with a lower risk of interference with aspirin inactivation of platelet cyclooxygenase-1. Proc Natl Acad Sci USA 2001;98: 14583–8
   PubMed Web of Science ®Google Scholar
• Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001;286: 954–9
   PubMed Web of Science ®Google Scholar
• Garcia Rodriguez LA, Varas C, Patrono C. Differential effects of aspirin and non-aspirin nonsteroidal anti-inflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women. Epidemiology 2000;11:382–7
   PubMed Web of Science ®Google Scholar
• Ray WA, Stein CM, Hall K, Daugherty JR, Griffin MR. Nonsteroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study. Lancet 2002;357:118–23
   Google Scholar
• Masferrer J, Zweifel BS, Manning PT, Hauser SD, Leahy KM, Smith WG, Isakson PC, Seibert K. Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. Proc Natl Acad Sci USA 1994;91:3228–32
   PubMed Web of Science ®Google Scholar
• Cipollone F, Prontera C, Pini B, Marini M, Fazia M, De Cesare D, Iezzi A, Ucchino S, Boccoli G, Saba V, Chiarelli F, Cuccurullo F, Mezzetti A. Overexpression of functionally coupled cyclooxygenase-2 and prostaglandin E synthase in symptomatic atherosclerotic plaques as a basis of prostaglandin E(2)-dependent plaque instability. Circulation 2001;104: 921–7
   PubMed Web of Science ®Google Scholar
• Cipollone F, Patrignani P, Greco A, Panara MR, Padovano R, Cuccurullo F, Patrono C, Rebuzzi AG, Liuzzo G, Quaranta G, Maseri A. Differential suppression of thromboxane biosynthesis by indobufen and aspirin in patients with unstable angina. Circulation 1997;96:1109–16
   PubMed Web of Science ®Google Scholar
• Cipollone F, Ciabattoni G, Patrignani P, Pasquale M, Di Gregorio D, Bucciarelli T, Davi G, Cuccurullo F, Patrono C. Oxidant stress and aspirin-insensitive thromboxane biosynthesis in severe unstable angina. Circulation 2000;102:1007–13
   PubMed Web of Science ®Google Scholar
• Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002;105:1650–5
   PubMed Web of Science ®Google Scholar
• Dallob A, Depré M, De Lepeleire I, Agrawal N, Musser B, Kher U, Van Hecken A, Wildonger L, Matthews C, De Schepper G, Riendeau D, Tanaka W, Gottesdiener K. MK-0663 a highly selective inhibitor of COX-2 in humans. Ann Rheum Dis 2000;59(Suppl 1):331
   PubMedGoogle Scholar
• Leung AT, Malmstrom K, Gallacher AE, Serembock B, Poor G, Beaulieu A, Castro R, Sanchez M, De Tora LM, Ng J. Efficacy and tolerability profile of etoricoxib in patients with osteoarthritis: a randomized, double-blind, placebo and active-comparator controlled 12-week efficacy trial. Curr Med Res Opin 2002;18:49–58
   PubMed Web of Science ®Google Scholar
• Chauret N, Yergey JA, Brideau C, Frieser RW, Mancini J, Riendeau D, Silva J, Styhler A, Trimble LA, Nicoll-Griffith DA. In vitro metabolism consideration, including activity testing of metabolites, in the discovery and selection of the COX-2 inhibitor etoricoxib (MK-0663). Bioorg Med Chem Lett 2001;11: 1059–62
   PubMed Web of Science ®Google Scholar
• Dallob A, De Lepeleire I, Van Hecken A, Porras A, Depré M, Mukhopadhyay S, Flynn M, Wildonger L, Tanaka W, De Schepper P. Ex vivo assays demonstrate potency and selectivity of the COX-2 inhibitor DFP after single dose administration. Inflamm Res 1999;48(Suppl2):S130–1
   PubMedGoogle Scholar